Although recent clinical data (KEYNOTE‐048 trial) have proven that ICB monotherapy is superior in PD‐L1‐expressing HNSCC as first‐line therapy compared with conventional chemotherapies [8, 32, 33], relevant basic research is still lacking. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.